Last reviewed · How we verify
Placebo (for canagliflozin)
A placebo contains no active pharmaceutical ingredient and produces no direct pharmacological effect.
A placebo contains no active pharmaceutical ingredient and produces no direct pharmacological effect. Used for Control arm in canagliflozin clinical trials.
At a glance
| Generic name | Placebo (for canagliflozin) |
|---|---|
| Sponsor | The Cleveland Clinic |
| Modality | Small molecule |
| Therapeutic area | Diabetes |
| Phase | FDA-approved |
Mechanism of action
Placebo is an inert substance used as a control in clinical trials to establish the efficacy of an active drug by comparison. Any observed effects in placebo groups are attributed to the placebo effect (psychological and contextual factors) rather than direct drug action. In this context, placebo was used as a comparator in canagliflozin clinical trials.
Approved indications
- Control arm in canagliflozin clinical trials
Common side effects
Key clinical trials
- Effect of Canagliflozin on Ultrafiltration & Fibrosis in Patients on Peritoneal Dialysis (PHASE2)
- Pathogenesis of Chronic Kidney Disease Associated With Metabolic Dysfunction- Associated Fatty Liver Disease (MAFLD) and Treatment Response of Oral Semaglutide. (NA)
- Efficacy and Safety Study of Canagliflozin (TA-7284) in Combination With Insulin in Patients With Type 2 Diabetes Mellitus (PHASE4)
- An Efficacy, Safety, and Tolerability Study for TA-7284 in Patients With Type 2 Diabetes (PHASE2)
- Efficacy and Safety Study of TA-7284 in Patients With Type 2 Diabetes (PHASE3)
- Confirmatory Study of MT-2412 in Japanese Patients With Type 2 Diabetes (Add-on Study of Canagliflozin) (PHASE3)
- Confirmatory Study of MT-2412 in Japanese Patients With Type 2 Diabetes (Add-on Study of Teneligliptin) (PHASE3)
- Canagliflozin in Advanced Renal Disease With MRI Endpoints (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Placebo (for canagliflozin) CI brief — competitive landscape report
- Placebo (for canagliflozin) updates RSS · CI watch RSS
- The Cleveland Clinic portfolio CI